Elekta to highlight high definition dynamic radiosurgery with Versa HD and Monaco at AAPM Annual Meeting

July 28, 2017

At the 59th American Association of Physicists in Medicine (AAPM) Annual Meeting & Exhibition July 30 - August 3 in Denver, Elekta (EKTA-B.ST) will showcase high definition dynamic radiosurgery (HDRS), a unique capability leveraging the core strengths of Versa HD™ linear accelerator and Monaco® treatment planning system.

Versa HD combines HDRS treatment capabilities and precision radiotherapy in a single platform. Equipped with sophisticated full-field, high definition beam-shaping technology and High Dose Rate mode, Versa HD offers the precision and speed necessary to deliver versatile stereotactic treatments throughout the body in standard treatment time slots. Monaco powers more efficient high definition planning with true Monte Carlo accuracy and advanced multi-criterial optimization.

Educational events

During AAPM, Elekta will host a series of educational events at the Hyatt Regency Denver. A luncheon symposium discussing the latest developments and data surrounding the dosimetry and commissioning of a hybrid MR-linac will take place Monday, July 31 from 12:30 - 1:30 p.m.

Elekta’s User Meeting, which is centered on new technology, proven QA processes and tips on how to best prepare for the future and the ever-changing health care landscape, will take place Saturday, July 29 from 10 a.m. - 5 p.m.

During the User Meeting, Sotiri Stathakis, PhD, Associate Professor, Radiation Oncology and Radiology, Cancer Therapy and Research Center, UT Health San Antonio Cancer Center will deliver a presentation titled Evaluation of dynamic conformal arc therapy for treatment of lung, liver and brain tumors. Key topics that Dr. Stathakis will address include:

The trend towards dynamic conformal arc treatments (DCAT) for lung stereotaxy using Monaco with Versa HD
The applicability of DCAT planning as a viable alternative to volumetric modulated arc therapy (VMAT) for lung and liver tumors treated with stereotactic body radiation therapy (SBRT)
How DCAT provides advantages in treatment delivery efficiency for lung and liver SBRT without compromising plan quality
Delivery accuracy of DCAT compared to VMAT on moving targets
Preliminary results from ongoing evaluations of DCAT in lung, liver and brain tumors

“A key challenge in the use of radiation therapy to treat tumors in the lung and liver is that these organs move during and between treatment sessions,” said Dr. Stathakis. “Preliminary data demonstrate that DCAT can address this challenge and enable accurate dose delivery to these tumors, which may improve patient outcomes.”

Visitors to Elekta booth #5047 also will have an opportunity to learn more about:

MOSAIQ®, the six-time Best in KLAS award winner that enables practice optimization through intelligent automation and actionable analytics
Venezia™, Elekta’s gynecological applicator which provides a new option for treating advanced-stage cervical cancer
Oncentra® Brachy, a comprehensive brachytherapy treatment planning software that helps save time by creating the optimal dose distribution
Leksell GammaPlan®, an integrated treatment planning and management software for Gamma Knife radiosurgery, including Leksell Gamma Knife® Icon™
iView Dose software, an EPID-based in vivo dosimetry solution that offers an essential safety check during radiation therapy
AQUA, a quality management system, which offers a full suite of workflow-oriented machine QA tasks and departmental resource management

For updates from the AAPM show floor, follow the Elekta Twitter handle, @Elekta. To learn more about Elekta at AAPM, visit www.elekta.com/AAPM.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, Email: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, Email: raven.canzeri@elekta.com
Time zone: EST: Eastern Standard Time

About Elekta
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com